## Risk of first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes (comparison between matched semaglutide vs other anti-diabetes medications groups)

			_			
Size/Group	Exposure Group	Comparison Group	Exposure Group Cases (Overall Risk)	Comparison Group Cases(Overall Risk)		HR (95% CI)
17,087	Semaglutide	Insulin	27 (0.16%)	73 (0.43%)	<b>⊢</b> ■	0.33 (0.21–0.51)
17,080	Semaglutide	Metformin	27 (0.16%)	68 (0.40%)	<b>⊢</b>	0.38 (0.24–0.59)
15,878	Semaglutide	DPP-4i	27 (0.17%)	62 (0.39%)	<b>⊢</b> ■──	0.40 (0.26–0.63)
15,288	Semaglutide	SGLT2i	26 (0.17%)	40 (0.26%)	<b>├</b>	0.60 (0.37–0.98)
16,503	Semaglutide	SU	27 (0.16%)	80 (0.49%)	<b>⊢</b> ■	0.31 (0.20–0.48)
10,847	Semaglutide	TZD	24 (0.22%)	51 (0.47%)	<b>⊢</b>	0.43 (0.26–0.70)
17,029	Semaglutide	Other GLP-1RAs	27 (0.16%)	44 (0.26%)	<b>⊢</b>	0.59 (0.37–0.95)
					0.10 0.20 0.40 0.70 <b>Hazard Ratio</b>	2.0 3.00 5.00 8.00 o (HR)